Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenografts

<p>Abstract</p> <p>Background</p> <p>Extracellular human sulfatases modulate growth factor signaling by alteration of the heparin/heparan sulfate proteoglycan (HSPG) 6-<it>O</it>-sulfation state. HSPGs bind to numerous growth factor ligands including fibrobl...

Full description

Bibliographic Details
Main Authors: Peterson Sarah M, Iskenderian Andrea, Cook Lynette, Romashko Alla, Tobin Kristen, Jones Michael, Norton Angela, Gómez-Yafal Alicia, Heartlein Michael W, Concino Michael F, Liaw Lucy, Martini Paolo GV
Format: Article
Language:English
Published: BMC 2010-08-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/427
_version_ 1818919336700542976
author Peterson Sarah M
Iskenderian Andrea
Cook Lynette
Romashko Alla
Tobin Kristen
Jones Michael
Norton Angela
Gómez-Yafal Alicia
Heartlein Michael W
Concino Michael F
Liaw Lucy
Martini Paolo GV
author_facet Peterson Sarah M
Iskenderian Andrea
Cook Lynette
Romashko Alla
Tobin Kristen
Jones Michael
Norton Angela
Gómez-Yafal Alicia
Heartlein Michael W
Concino Michael F
Liaw Lucy
Martini Paolo GV
author_sort Peterson Sarah M
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Extracellular human sulfatases modulate growth factor signaling by alteration of the heparin/heparan sulfate proteoglycan (HSPG) 6-<it>O</it>-sulfation state. HSPGs bind to numerous growth factor ligands including fibroblast growth factors (FGF), epidermal growth factors (EGF), and vascular endothelial growth factors (VEGF), and are critically important in the context of cancer cell growth, invasion, and metastasis. We hypothesized that sulfatase activity in the tumor microenvironment would regulate tumor growth <it>in vivo</it>.</p> <p>Methods</p> <p>We established a model of stable expression of sulfatases in the human breast cancer cell line MDA-MB-231 and purified recombinant human Sulfatase 2 (rhSulf2) for exogenous administration. <it>In vitro </it>studies were performed to measure effects on breast cancer cell invasion and proliferation, and groups were statistically compared using Student's t-test. The effects of hSulf2 on tumor progression were tested using <it>in vivo </it>xenografts with two methods. First, MDA-MB-231 cells stably expressing hSulf1, hSulf2, or both hSulf1/hSulf2 were grown as xenografts and the resulting tumor growth and vascularization was compared to controls. Secondly, wild type MDA-MB-231 xenografts were treated by short-term intratumoral injection with rhSulf2 or vehicle during tumor growth. Ultrasound analysis was also used to complement caliper measurement to monitor tumor growth. <it>In vivo </it>studies were statistically analyzed using Student's t test.</p> <p>Results</p> <p><it>In vitro</it>, stable expression of hSulf2 or administration of rhSulf2 in breast cancer cells decreased cell proliferation and invasion, corresponding to an inhibition of ERK activation. Stable expression of the sulfatases in xenografts significantly suppressed tumor growth, with complete regression of tumors expressing both hSulf1 and hSulf2 and significantly smaller tumor volumes in groups expressing hSulf1 or hSulf2 compared to control xenografts. Despite significant suppression of tumor volume, sulfatases did not affect vascular density within the tumors. By contrast, transient exogenous treatment of MDA-MB-231 xenografts with rhSulf2 was not sufficient to inhibit or reverse tumor growth.</p> <p>Conclusion</p> <p>These data indicate that <it>in vivo </it>progression of human breast cancer xenografts can be inhibited with sulfatase expression, and therapeutic effect requires constant delivery at the tumor site. Our results support a direct effect of sulfatases on tumor growth or invasion, rather than an effect in the stromal compartment.</p>
first_indexed 2024-12-20T01:04:15Z
format Article
id doaj.art-e6955f3168a140e0a95768edca7a471e
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-12-20T01:04:15Z
publishDate 2010-08-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-e6955f3168a140e0a95768edca7a471e2022-12-21T19:58:54ZengBMCBMC Cancer1471-24072010-08-0110142710.1186/1471-2407-10-427Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenograftsPeterson Sarah MIskenderian AndreaCook LynetteRomashko AllaTobin KristenJones MichaelNorton AngelaGómez-Yafal AliciaHeartlein Michael WConcino Michael FLiaw LucyMartini Paolo GV<p>Abstract</p> <p>Background</p> <p>Extracellular human sulfatases modulate growth factor signaling by alteration of the heparin/heparan sulfate proteoglycan (HSPG) 6-<it>O</it>-sulfation state. HSPGs bind to numerous growth factor ligands including fibroblast growth factors (FGF), epidermal growth factors (EGF), and vascular endothelial growth factors (VEGF), and are critically important in the context of cancer cell growth, invasion, and metastasis. We hypothesized that sulfatase activity in the tumor microenvironment would regulate tumor growth <it>in vivo</it>.</p> <p>Methods</p> <p>We established a model of stable expression of sulfatases in the human breast cancer cell line MDA-MB-231 and purified recombinant human Sulfatase 2 (rhSulf2) for exogenous administration. <it>In vitro </it>studies were performed to measure effects on breast cancer cell invasion and proliferation, and groups were statistically compared using Student's t-test. The effects of hSulf2 on tumor progression were tested using <it>in vivo </it>xenografts with two methods. First, MDA-MB-231 cells stably expressing hSulf1, hSulf2, or both hSulf1/hSulf2 were grown as xenografts and the resulting tumor growth and vascularization was compared to controls. Secondly, wild type MDA-MB-231 xenografts were treated by short-term intratumoral injection with rhSulf2 or vehicle during tumor growth. Ultrasound analysis was also used to complement caliper measurement to monitor tumor growth. <it>In vivo </it>studies were statistically analyzed using Student's t test.</p> <p>Results</p> <p><it>In vitro</it>, stable expression of hSulf2 or administration of rhSulf2 in breast cancer cells decreased cell proliferation and invasion, corresponding to an inhibition of ERK activation. Stable expression of the sulfatases in xenografts significantly suppressed tumor growth, with complete regression of tumors expressing both hSulf1 and hSulf2 and significantly smaller tumor volumes in groups expressing hSulf1 or hSulf2 compared to control xenografts. Despite significant suppression of tumor volume, sulfatases did not affect vascular density within the tumors. By contrast, transient exogenous treatment of MDA-MB-231 xenografts with rhSulf2 was not sufficient to inhibit or reverse tumor growth.</p> <p>Conclusion</p> <p>These data indicate that <it>in vivo </it>progression of human breast cancer xenografts can be inhibited with sulfatase expression, and therapeutic effect requires constant delivery at the tumor site. Our results support a direct effect of sulfatases on tumor growth or invasion, rather than an effect in the stromal compartment.</p>http://www.biomedcentral.com/1471-2407/10/427
spellingShingle Peterson Sarah M
Iskenderian Andrea
Cook Lynette
Romashko Alla
Tobin Kristen
Jones Michael
Norton Angela
Gómez-Yafal Alicia
Heartlein Michael W
Concino Michael F
Liaw Lucy
Martini Paolo GV
Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenografts
BMC Cancer
title Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenografts
title_full Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenografts
title_fullStr Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenografts
title_full_unstemmed Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenografts
title_short Human Sulfatase 2 inhibits <it>in vivo </it>tumor growth of MDA-MB-231 human breast cancer xenografts
title_sort human sulfatase 2 inhibits it in vivo it tumor growth of mda mb 231 human breast cancer xenografts
url http://www.biomedcentral.com/1471-2407/10/427
work_keys_str_mv AT petersonsarahm humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT iskenderianandrea humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT cooklynette humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT romashkoalla humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT tobinkristen humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT jonesmichael humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT nortonangela humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT gomezyafalalicia humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT heartleinmichaelw humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT concinomichaelf humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT liawlucy humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts
AT martinipaologv humansulfatase2inhibitsitinvivoittumorgrowthofmdamb231humanbreastcancerxenografts